▲ At the fall conference of the Korean Geriatric Psychiatry Association on November 10, Dr. Youngsun Choi, head of Gemvax & KAEL R&D Department, is explaining the mechanism of action of GV1001.
【Health and Welfare News】Gemvax & KAEL (hereinafter referred to as Gemvax) announced on the 13th that it was invited to the fall conference of the Korean Geriatric Psychiatry Association and presented the research results of GV1001, which is being developed as a treatment for Alzheimer’s disease.
Dr. Youngsun Choi, head of Gemvax’s R&D department, who made the presentation, introduced the research results and development status of GV1001 over the past 10 years, including preclinical, clinical, and mechanism of action.
Dr. Young-seon Choi said, “The future treatment paradigm for Alzheimer’s disease lies in disease control treatment,” and “GV1001, a multi-mechanism drug, is a disease control drug that simultaneously exhibits various effects such as anti-inflammatory, antioxidant, mitochondrial protection, and improvement of the immune environment in the brain, and is a new Alzheimer’s drug. “It presents an approach to treating the disease,” he said.
In particular, regarding the recently discovered mechanism of action of the drug, it is explained that “GV1001 inhibits inflammation (neuroinflammation) in the brain by binding to the gonadotropin-releasing hormone receptor (GnRHR) present in microglia and astrocytes.” , predicted, “As the mechanism for the drug effect of GV1001 has been identified, ongoing clinical trials will gain further momentum.”
Experts attending the conference showed great interest in drug safety, which is a strength of GV1001, and asked questions about indications, mechanisms, and ongoing global clinical trials.
The domestic phase 3 clinical trial of GV1001, which successfully completed the domestic phase 2 clinical trial for Alzheimer’s disease, will be conducted by Samsung Pharmaceuticals, which acquired the domestic license last May.
Gemvax is currently focusing its capabilities on developing specialized treatments for neurodegenerative diseases by conducting a global phase 2 clinical trial for Alzheimer’s disease and Korea’s first progressive supranuclear palsy clinical trial in the United States and seven European countries.
Please note that posts that are not related to the content of the article or that defame others, such as using profanity, may be deleted without notice by the administrator.
2023-11-13 00:00:00
#Health #Welfare #News #Gemvax #introduces #dementia #treatment #drug #GV1001 #Society #Geriatric #Medicine
